Difference between revisions of "Team:Newcastle/Results/Endophyte"
| Line 226: | Line 226: | ||
<img src="https://static.igem.org/mediawiki/2018/4/41/T--Newcastle--Transformation_control.jpeg" height="400" width="400"> | <img src="https://static.igem.org/mediawiki/2018/4/41/T--Newcastle--Transformation_control.jpeg" height="400" width="400"> | ||
| + | |||
| + | <p><font size="3">Figure 12. Pseudomonas sp. DSM 25356 transformed with sterile water (Control) plated on TSA containing gentamicin (10 μg/ml).</font></p> | ||
| + | |||
<h3 class="h2">Week Beginning 17/09</h3> | <h3 class="h2">Week Beginning 17/09</h3> | ||
| Line 236: | Line 239: | ||
<!-- [Image: SmR Replicate 1] <img src=""> | <!-- [Image: SmR Replicate 1] <img src=""> | ||
================================================== --> | ================================================== --> | ||
| + | |||
| + | |||
| + | <img src="https://static.igem.org/mediawiki/2018/c/cc/T--Newcastle--SmR_Replicate_1.jpeg" height="400" width="400"> | ||
<p><font size="3">Figure 13. E. coli strain DH5α transformed with streptomycin resistance part BBa_K2797002 plated on LB agar containing streptomycin (50 μg/ml).</font></p> | <p><font size="3">Figure 13. E. coli strain DH5α transformed with streptomycin resistance part BBa_K2797002 plated on LB agar containing streptomycin (50 μg/ml).</font></p> | ||
| Line 243: | Line 249: | ||
================================================== --> | ================================================== --> | ||
| + | <img src="https://static.igem.org/mediawiki/2018/6/6a/T--Newcastle--SmR_Positive_Control.jpeg" height="400" width="400"> | ||
<p><font size="3">Figure 15. E. coli strain DH5α transformed with Gibson assembly positive control plated on LB agar containing ampicillin (100 µg/ml)</font></p> | <p><font size="3">Figure 15. E. coli strain DH5α transformed with Gibson assembly positive control plated on LB agar containing ampicillin (100 µg/ml)</font></p> | ||
| Line 248: | Line 255: | ||
<!-- [Image: SmR Negative Control] <img src=""> | <!-- [Image: SmR Negative Control] <img src=""> | ||
================================================== --> | ================================================== --> | ||
| + | |||
| + | <img src="https://static.igem.org/mediawiki/2018/6/6b/T--Newcastle--SmR_Negative_Control.jpeg" height="400" width="400"> | ||
| + | |||
<p><font size="3">Figure 16. E. coli strain DH5α transformed with sterile water (negative control) plated on LB agar containing streptomycin (50 µg/ml)</font></p> | <p><font size="3">Figure 16. E. coli strain DH5α transformed with sterile water (negative control) plated on LB agar containing streptomycin (50 µg/ml)</font></p> | ||
| Line 254: | Line 264: | ||
<!-- [Image: SmR Streak] <img src=""> | <!-- [Image: SmR Streak] <img src=""> | ||
================================================== --> | ================================================== --> | ||
| + | |||
| + | |||
| + | <img src="https://static.igem.org/mediawiki/2018/e/e7/T--Newcastle--SmR_Streak.jpeg" height="400" width="400"> | ||
<p><font size="3">Figure 17. E. coli strain DH5α transformed with streptomycin resistance part BBa_K2797002 plated on LB agar containing streptomycin (50 μg/ml)</font></p> | <p><font size="3">Figure 17. E. coli strain DH5α transformed with streptomycin resistance part BBa_K2797002 plated on LB agar containing streptomycin (50 μg/ml)</font></p> | ||
| Line 260: | Line 273: | ||
<!-- [Image: SmR Chloramphenicol] <img src=""> | <!-- [Image: SmR Chloramphenicol] <img src=""> | ||
================================================== --> | ================================================== --> | ||
| + | |||
| + | |||
| + | <img src="https://static.igem.org/mediawiki/2018/4/4f/T--Newcastle--SmR_Chloramphenicol.jpeg" height="400" width="400"> | ||
<p><font size="3">Figure 18. E. coli strain DH5α carrying the streptomycin resistance part BBa_K2797002 plated on LB agar containing chloramphenicol (25 μg/ml). The part is in the pSB1C3 backbone conferring resistance to chloramphenicol.</font></p> | <p><font size="3">Figure 18. E. coli strain DH5α carrying the streptomycin resistance part BBa_K2797002 plated on LB agar containing chloramphenicol (25 μg/ml). The part is in the pSB1C3 backbone conferring resistance to chloramphenicol.</font></p> | ||
| Line 271: | Line 287: | ||
<!-- [Graph: K2797002 Characterisation] <img src=""> | <!-- [Graph: K2797002 Characterisation] <img src=""> | ||
================================================== --> | ================================================== --> | ||
| + | |||
Revision as of 14:46, 12 October 2018
Alternative Roots
Endophytic Chassis Results
RESULTS
Developing Pseudomonas as a new endophytic chassis
Week Beginning 06/08
Pure cultures were obtained following plating out of the sample that arrived from DSMZ.
Week Beginning 13/08
Screening on tryptone soy agar (TSA) showed Pseudomonas sp. to be highly resistant to chloramphenicol with lawns forming on plates containing the highest concentration of chloramphenicol tested (Figure 1).
Figure 2. Pseudomonas sp. DSM 25356 plated on tryptone soy agar containing chloramphenicol (100 µg/ml)
Screening on agar also found Pseudomonas sp. to be resistant to kanamycin and carbenicillin with lawns forming on plates containing the highest concentration of chloramphenicol tested (Figure 1)
Figure 3. Pseudomonas sp. DSM 25356 plated on tryptone soy agar containing carbenicillin (100 µg/ml)
Figure 4. Pseudomonas sp. DSM 25356 plated on tryptone soy agar containing carbenicillin (100 µg/ml)
The results showed that Pseudomonas sp. was susceptible to both streptomycin (Figure 5) and gentamicin (Figure 6) with no colony forming units visible on either the 50 µg/ml or 100 µg/ml plates for both antibiotics
Figure 5. Pseudomonas sp. DSM 25356 plated on tryptone soy agar containing streptomycin (100 µg/ml)
Figure 6. Pseudomonas sp. DSM 25356 plated on tryptone soy agar containing gentamicin (100 µg/ml)
Week beginning 20/08
Week beginning 27/08
Week beginning 03/09
The results of our minimum inhibitory concentration experiments showed a clear dose response between antibiotic concentration and growth of Pseudomonas sp. for both streptomycin and gentamicin (Figures 7 and 8). Gentamicin was found to be the more effective antibiotic with a concentration of 1.5 µg/ml sufficient to prevent growth. A concentration of 6.0 µg/ml of streptomycin was required to prevent growth. A slight increase in absorbance was observed for the positive control for both antibiotics. This is likely due to release of compounds by bacterial cells upon death.
Figure 7. Pseudomonas sp. DSM 25356 grown in tryptone soy broth containing gentamicin at varying concentrations. Cells were grown in 96-well plate format in 200 µl volumes at 37 °C over 24 hours. (n=4 replicates, error bars are standard error of the mean)
Figure 8. Pseudomonas sp. DSM 25356 grown in tryptone soy broth containing streptomycin at varying concentrations. Cells were grown in 96-well plate format in 200 µl volumes at 37 °C over 24 hours. (n=4 replicates, error bars are standard error of the mean).
Week Beginning 10/09
Miniprep DNA concentrations,
Transformation plates
Table of DNA concentrations and CFUS
Prior to tran
Figure 8. Pseudomonas sp. DSM 25356 plated on tryptone soy agar containing gentamicin (6 µg/ml)
Figure 9. Pseudomonas sp. DSM 25356 transformed with gentamicin resistance plasmid from miniprep 1 plated on TSA containing gentamicin (10 μg/ml).
Figure 10. Pseudomonas sp. DSM 25356 transformed with gentamicin resistance plasmid from miniprep 2 plated on TSA containing gentamicin (10 μg/ml).
Figure 11. Pseudomonas sp. DSM 25356 transformed with gentamicin resistance plasmid from miniprep 3 plated on TSA containing gentamicin (10 μg/ml).
Figure 12. Pseudomonas sp. DSM 25356 transformed with sterile water (Control) plated on TSA containing gentamicin (10 μg/ml).
Week Beginning 17/09
Gibson assembly contents table?
Figure 13. E. coli strain DH5α transformed with streptomycin resistance part BBa_K2797002 plated on LB agar containing streptomycin (50 μg/ml).
Figure 15. E. coli strain DH5α transformed with Gibson assembly positive control plated on LB agar containing ampicillin (100 µg/ml)
Figure 16. E. coli strain DH5α transformed with sterile water (negative control) plated on LB agar containing streptomycin (50 µg/ml)
Figure 17. E. coli strain DH5α transformed with streptomycin resistance part BBa_K2797002 plated on LB agar containing streptomycin (50 μg/ml)
Figure 18. E. coli strain DH5α carrying the streptomycin resistance part BBa_K2797002 plated on LB agar containing chloramphenicol (25 μg/ml). The part is in the pSB1C3 backbone conferring resistance to chloramphenicol.
Week Beginning 24/09
Figure 19. E. coli DH5α with or without the BBa_K2797002 part in pSB1C3 were grown in LB medium containing streptomycin at varying concentrations. Cells were grown in 96-well plate format in 200 μl volumes at 37 °C over 24 hours. (n=3 replicates, error bars are standard error of the mean).
Week Beginning 01/10
Figure 20. Pseudomonas sp. with or without gentamicin resistance plasmid were grown in tryptone soy broth containing gentamicin at varying concentrations. Cells were grown in a 96-well plate format in 200 μl volumes at 28 °C over 24 hours. (n=5 replicates, error bats are standard error of the mean)
REFERENCES & Attributions
Attributions: Frank Eardley